PAD4 Monoclonal Antibody (Clone 6D8)

Protein arginine deiminase 4 (PAD4) catalyzes the conversion of arginine residues to citrulline within cellular protein substrates, resulting in the loss of a positive charge, which can alter protein structure and/or function.{45610} It is expressed in neutrophils, as well as a variety of tissues, including the brain, liver, lung, and kidney.{45610,45611,18134} PAD4 has a key role in NETosis, a lytic form of cell death characterized by the release of neutrophil extracellular traps (NETs).{45610} Upon neutrophil activation, PAD4 translocates to the nucleus where it citrullinates histones, initiating chromatin decondensation and the release of NETs.{45611,19778,61223} Neutrophils isolated from Pad4-/- mice exhibit decreased citrullination of histone H3 under both basal and LPS-stimulated conditions and are defective for NET formation in response to stimulation with LPS, phorbol 12-myristate 13-acetate (PMA; Item No. 10008014), or hydrogen peroxide.{19778} Pad4-/- mice exhibit larger lesions than wild-type mice in a model of necrotizing fasciitis induced by M1 group A S. pyogenes lacking the extracellular DNase Sda1. Pad4-deficient mice also exhibit reduced infarct size in a model of myocardial ischemia-reperfusion injury and reduced tumor growth in a Lewis lung carcinoma model.{45612,45611} Serum PAD4 autoantibodies have been found in patients with rheumatoid arthritis and are associated with disease severity.{19300} Cayman's PAD4 Monoclonal Antibody (Clone 6D8) can be used for ELISA and Western blot (WB) applications. The antibody recognizes PAD4 at 74 kDa from human samples.